Molecular immunohematology is rapidly being adopted in transfusion medicine. Molecular information has lead to advanced care in HDFN, and is a necessary tool for the IRL. Now, molecular immunohematology is poised to address non-ABO hemolytic transfusion reactions including the prevention of alloimmunization through "dry" (genotype) matching, antibody evanescence, and the appropriate support chronic transfusion and marrow transplantation. This education session is designed to challenge the transfusion scientific community to think about the impact that molecular immunohematology has on complex problems in transfusion. How can red cell alloimmunization be addressed? What advantages can be had by "dry" (genotype) matching donor "liquid organs" to patients? How can blood group genotyping be used to improve the support of the chronically transfused patient? Join us for presentations and discussions on leading edge applications in molecular immunohematology.